Bayer (XTRA:BAYN) Could Be 24% Undervalued As $2.2b Ohio Drug Hub Takes Shape

What happened: Bayer (XTRA:BAYN) has priced a new pharmaceutical manufacturing hub in New Albany, Ohio at US$2.2b, aimed at specialty treatments in oncology, cardiovascular, and renal care. Key numbers: US$2.2b Ohio hub. Why it matters: The most followed valuation narrative sees Bayer 24% undervalued, with margin expansion and cost savings expected to lift long-term net margins. Risks cited include glyphosate and PCB litigation costs and crop protection pricing pressure.

Bayer (XTRA:BAYN) has priced a new pharmaceutical manufacturing hub in New Albany, Ohio at US$2.2b, aimed at specialty treatments in oncology, cardiovascular, and renal care.

The most followed valuation narrative sees Bayer 24% undervalued, with margin expansion and cost savings expected to lift long-term net margins. Risks cited include glyphosate and PCB litigation costs and crop protection pricing pressure.